Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies

Even FDA’s Peter Marks is worried about the commercial viability of gene and cell therapies

When blue­bird bio’s gene ther­a­py to treat be­ta tha­lassemia won Eu­ro­pean ap­proval in 2019, the near­ly $2 mil­lion per pa­tient price tag for the po­ten­tial cure seemed like a sur­mount­able hur­dle. Fast for­ward two years lat­er, and blue­bird has with­drawn Zyn­te­glo, the be­ta thal drug, along with the rest of its gene ther­a­py port­fo­lio from …

Even FDA’s Peter Marks is worried about the commercial viability of gene and cell therapies Read More »